Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IMA201 Product · 1 trial · 4 indications
| Arm | Type | Description |
|---|---|---|
| IMA201 Product | EXPERIMENTAL | * Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide * One dose of IMA201 product will be infused intravenously. Up to four dose levels will be evaluated. At least two patients per cohort will be treated. * Post-infusion of IMA201 product, administration of low-dose recombinant human interleukin-2 |
| Name | Type | Description |
|---|---|---|
| IMA201 Product | BIOLOGICAL | The cell dose will be based on viable CD3+CD8+ HLA-Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula. |
| IMADetect® | DIAGNOSTIC_TEST | IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in clinical trials with investigational IMA201 therapy. IMADetect® is intended for investigational use only. |
Inclusion Criteria: * Patient ≥ 18 years of age * Pathologically confirmed advanced and/or metastatic solid tumor * Patients may enter screening procedure before, during, or after the last available indicated standard of care treatment. There is no limitation for prior anti cancer treatments. * Eas...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
IMA201 Product is an investigational monoclonal antibody being developed for the treatment of solid tumors, including recurrent and refractory solid tumors. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
IMA201 Product is being developed by Immatics N.V., a biopharmaceutical company traded on the stock exchange under the ticker symbol IMTX. The company is conducting clinical research on this investigational therapy for solid tumors.
IMA201 Product is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved for commercial use. The Phase 1 trial has been completed, and the drug remains under investigation for the treatment of solid tumors.
IMA201 Product has been studied in one clinical trial with the identifier NCT03247309, titled "TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101)." This Phase 1 trial enrolled 7 participants and was conducted in the United States and Germany.
IMA201 Product is associated with the clinical trial ACTengine IMA201-101, which is the study name for the Phase 1 trial of this investigational therapy. The trial evaluated the product in patients with solid tumors, including recurrent and refractory cases.